PMID- 30775414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 2352-0477 (Print)
IS  - 2352-0477 (Electronic)
IS  - 2352-0477 (Linking)
VI  - 6
DP  - 2019
TI  - Cardiovascular magnetic resonance T2* mapping for structural alterations in 
      hypertrophic cardiomyopathy.
PG  - 78-84
LID - 10.1016/j.ejro.2019.01.007 [doi]
AB  - PURPOSE: Hypertrophic cardiomyopathy (HCM) is characterized by a heterogeneous 
      morphology and variable prognosis. A mismatch between left ventricular mass (LVM) 
      and microvascular circulation with corresponding relative ischemia has been 
      implicated to cause myocardial replacement fibrosis that deteriorates prognosis. 
      Besides parametric T1 mapping, Cardiovascular Magnetic Resonance (CMR) T2* 
      mapping is able to identify ischemia as well as fibrosis in cardiac and 
      extracardiac diseases. Therefore, we aimed to investigate the value of T2* 
      mapping to characterize structural alterations in patients with HCM. METHODS: CMR 
      was performed on a 1.5 T MR imaging system (Achieva, Philips, Best, Netherlands) 
      using a 5-channel coil in patients with HCM (n = 103, 50.6 +/- 16.4 years) and in 
      age- and gender-matched controls (n = 20, 44.8 +/- 16.9 years). T2* mapping (1 
      midventricular short axis slice) was acquired in addition to late gadolinium 
      enhancement (LGE). T2* values were compared between patients with HCM and 
      controls as well as between HCM patients with- and without fibrosis. RESULTS: HCM 
      patients showed significantly decreased T2* values compared to controls 
      (26.2 +/- 4.6 vs. 31.3 +/- 4.3 ms, p < 0.001). Especially patients with myocardial 
      fibrosis presented with decreased T2* values in comparison to those without 
      fibrosis (25.2 +/- 4.0 vs. 28.7 +/- 5.3 ms, p = 0.003). A regression model including 
      maximum wall thickness, LVM and T2* values provided good overall diagnostic 
      accuracy of 80% to diagnose HCM with and without fibrosis. CONCLUSION: In this 
      study, parametric mapping identified lower T2* values in HCM patients compared to 
      controls, especially in a sub-group of patients with myocardial fibrosis. As 
      myocardial fibrosis has been suggested to influence prognosis of patients with 
      HCM, T2* mapping may add information for identifying a higher risk sub-group of 
      HCM patients.
FAU - Gastl, Mareike
AU  - Gastl M
AD  - Department of Cardiology, University Heart Center, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
AD  - Institute for Biomedical Engineering, University and ETH Zurich Gloriastrasse 35, 
      8092 Zurich, Switzerland.
AD  - Dept. Cardiology, Pneumology and Angiology, Heinrich Heine University, 
      Dusseldorf, Germany.
FAU - Gotschy, Alexander
AU  - Gotschy A
AD  - Department of Cardiology, University Heart Center, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
AD  - Institute for Biomedical Engineering, University and ETH Zurich Gloriastrasse 35, 
      8092 Zurich, Switzerland.
FAU - von Spiczak, Jochen
AU  - von Spiczak J
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
FAU - Polacin, Malgorzata
AU  - Polacin M
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
FAU - Bonner, Florian
AU  - Bonner F
AD  - Dept. Cardiology, Pneumology and Angiology, Heinrich Heine University, 
      Dusseldorf, Germany.
FAU - Gruner, Christiane
AU  - Gruner C
AD  - Department of Cardiology, University Heart Center, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Dept. Cardiology, Pneumology and Angiology, Heinrich Heine University, 
      Dusseldorf, Germany.
FAU - Ruschitzka, Frank
AU  - Ruschitzka F
AD  - Department of Cardiology, University Heart Center, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
FAU - Alkadhi, Hatem
AU  - Alkadhi H
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
FAU - Kozerke, Sebastian
AU  - Kozerke S
AD  - Institute for Biomedical Engineering, University and ETH Zurich Gloriastrasse 35, 
      8092 Zurich, Switzerland.
FAU - Manka, Robert
AU  - Manka R
AD  - Department of Cardiology, University Heart Center, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
AD  - Institute for Biomedical Engineering, University and ETH Zurich Gloriastrasse 35, 
      8092 Zurich, Switzerland.
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, 
      Raemistrasse 100, 8091, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20190204
PL  - England
TA  - Eur J Radiol Open
JT  - European journal of radiology open
JID - 101650225
EIN - Eur J Radiol Open. 2020 Dec 17;8:100308. PMID: 33364261
PMC - PMC6365365
OTO - NOTNLM
OT  - CMR
OT  - Fibrosis
OT  - Hypertrophic cardiomyopathy
OT  - T2* mapping
EDAT- 2019/02/19 06:00
MHDA- 2019/02/19 06:01
PMCR- 2019/02/04
CRDT- 2019/02/19 06:00
PHST- 2019/01/16 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/02/19 06:00 [entrez]
PHST- 2019/02/19 06:00 [pubmed]
PHST- 2019/02/19 06:01 [medline]
PHST- 2019/02/04 00:00 [pmc-release]
AID - S2352-0477(19)30006-1 [pii]
AID - 10.1016/j.ejro.2019.01.007 [doi]
PST - epublish
SO  - Eur J Radiol Open. 2019 Feb 4;6:78-84. doi: 10.1016/j.ejro.2019.01.007. 
      eCollection 2019.